0001209191-23-013006.txt : 20230224 0001209191-23-013006.hdr.sgml : 20230224 20230224203520 ACCESSION NUMBER: 0001209191-23-013006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230222 FILED AS OF DATE: 20230224 DATE AS OF CHANGE: 20230224 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HANLY ANN M. CENTRAL INDEX KEY: 0001854528 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 23669673 MAIL ADDRESS: STREET 1: C/O VIR BIOTECHNOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-22 0 0001706431 Vir Biotechnology, Inc. VIR 0001854528 HANLY ANN M. C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 1 0 0 Chief Technology Officer Common Stock 2023-02-22 4 A 0 37500 0.00 A 119505 D Common Stock 2023-02-23 4 S 0 2302 25.973 D 117203 D Common Stock 11.52 I See footnote Stock Option (Right to Buy) 27.01 2023-02-22 4 A 0 55000 0.00 A 2033-02-21 Common Stock 55000 55000 D Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Includes 532 shares of common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program. Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child. 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter. /s/ Howard Horn, Attorney-in-Fact 2023-02-24